Aision: Prophylactic drugs to prevent the development of stress-induced mood and anxiety disorders

Unmet Medical Need:  Affective disorders, such as major depressive disorder and post-traumatic stress disorder (PTSD), are currently treated from a symptom-suppression approach. Existing drugs only mitigate symptomatology, but do not cure or prevent the chronic disease itself.

Envisioned Healthcare Product:  The team is developing the first drugs that would prevent the development of stress-induced psychiatric disorders. The target product is an orally available, single dose short-acting small molecule that provides at least one month of stress resilience enhancement, decreasing the incidence of PTSD by at least 20%. This represents a paradigm shift in psychiatry; using pharmacotherapy to prevent mental illness.

Stage of Development: Validation

September 2016 Article

November 2016 the Atlantic Article

February 2017 Science Daily Article

April 2017 Washington Post Article

Funding Cycle: 2017-2018